Recombinant human Prostatic Acid Phosphatase/ACPP
Catalog Number: B3002-420

Description: DOGENE Recombinant Human Prostatic Acid Phosphatase/ACPP is produced with mammalian cells expression system. Target protein is expressed with sequence (Lys33-Asp386) of Human acpp (Uniprot #P15309) fused with a polyhistidine tag at the C-terminus.

Purity: Greater than 95% as determined by SEC-HPLC.
Greater than 95% as determined by reducing SDS-PAGE.

Endotoxin: Less than 0.1 ng/ug (1 IEU/ug)

Formulation: DOGENE Recombinant Human ACPP was lyophilized at 1mg/ml in 20mM PBS.

Storage: Lyophilized Recombinant Human ACPP although stable at room temperature for 3 weeks, should be stored desiccated below -18 °C. Upon reconstitution Recombinant Human ACPP should be stored at 4 °C between 2-7 days and aliquots of reconstituted samples are stable up to 3 months below -18 °C for future use.

Reconstitution: It is recommended to reconstitute the lyophilized Recombinant Human ACPP in PBS not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Please avoid freeze-thaw cycles.
Background
ACPP, a single-pass type I membrane protein, also known as Prostatic acid phosphatase, belongs to the histidine acid phosphatase family. ACPP can catalyze the hydrolysis of member of phosphate monoesters, including phosphorylated protein. ACPP can high expression in metastasized prostate cancer, moderately expression level in bone diseases, blood cell disease, and the concentration of ACPP is used to monitor and assess the progression of prostate cancer. The optimum PH of ACPP is from 4 to 6, its activity can be inhibited by L(+) -tartrate.